.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,575,122

« Back to Dashboard

Details for Patent: 8,575,122

Title:Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s): Lichter; Jay (Rancho Santa Fe, CA), Lebel; Carl (Malibu, CA), Piu; Fabrice (San Diego, CA), Trammel; Andrew M. (Olathe, KS)
Assignee: Otonomy, Inc. (San Diego, CA)
Filing Date:Apr 26, 2010
Application Number:12/767,461
Claims:1. A pharmaceutical otic formulation comprising: between about 0.2% to about 20% by weight of an agent that modulates the Atoh1 gene or pharmaceutically acceptable prodrug or salt thereof; and a thermoreversible gel having a gelation temperature between about room temperature and about body temperature; a non-gelation viscosity that allows injection at or about room temperature with a needle having a gauge in the range of 18-31 through the tympanic membrane to an area on or near the round window membrane, and with a gelation viscosity between about 15,000 cP and about 1,000,000 cP; wherein the otic formulation provides a sustained release of an effective amount of the agent to the inner ear for a period of from 5 days to 6 months, and wherein the agent is essentially in the form of micronized particles.

2. The formulation of claim 1, wherein the agent comprises a vector engineered to carry the human Atoh1 gene.

3. The formulation of claim 1, wherein the agent that modulates the Atoh1 gene induces auris sensory hair cell regeneration.

4. The formulation of claim 1, wherein the thermoreversible gel comprises a polymer composed of polyoxypropylene and polyoxyethylene.

5. The formulation of claim 1, wherein the thermoreversible gel comprises between about 16% to about 21% by weight of polymers composed of polyoxypropylene and polyoxyethylene.

6. A method for treating an otic disease or condition comprising administering to a patient in need thereof a composition, the composition comprising: between about 0.2% to about 20% by weight of an agent that modulates the Atoh1 gene or pharmaceutically acceptable prodrug or salt thereof; and a thermoreversible gel having a gelation temperature between about room temperature and about body temperature; a non-gelation viscosity that allows injection at or about room temperature with a needle having a gauge in the range of 18-31 through the tympanic membrane to an area on or near the round window membrane, and with a gelation viscosity between about 15,000 cP and about 1,000,000 cP; wherein the composition provides a sustained release of an effective amount of the agent to the inner ear of the patient for a period of from 5 days to 6 months, and wherein the agent is essentially in the form of micronized particles.

7. The method of claim 6, wherein the agent comprises a vector engineered to carry the human Atoh1 gene.

8. The method of claim 6, wherein the agent that modulates the Atoh1 gene induces auris sensory hair cell regeneration.

9. The method of claim 6, wherein the thermoreversible gel comprises a polymer composed of polyoxypropylene and polyoxyethylene.

10. The method of claim 6, wherein the thermoreversible gel comprises between about 16% to about 21% by weight of polymers composed of polyoxypropylene and polyoxyethylene.

11. The method of claim 6, wherein the otic disease or condition is hearing loss.

12. The method of claim 11, wherein the hearing loss is from Meniere's disease, sudden sensorineural hearing loss, noise induced hearing loss, age related hearing loss, auto immune ear disease or tinnitus.

13. The method of claim 6, wherein the pharmaceutical composition is administered at or near the round window membrane of the patient in need.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc